Search
Research finds new Rx target for childhood cancer
- OPACC
- Apr 16, 2019
- 1 min read
Research led by Michael Lan, Ph.D., Professor of Pediatrics and Genetics at LSU Health New Orleans School of Medicine, found that a compound named 5'-iodotubercidin (5'-IT) suppresses the growth of neuroblastoma cells and identified a potential new therapeutic approach for the disease.
Recent Posts
See AllDuring cancer treatment, children can face hurdles to maintaining healthy eating. Chemotherapy has many side effects, including loss of...
Quality of life improvements can be made if clinicians better understand auditory attention decay after cancer treatment in pediatric...
A team of experts, issuing a statement on behalf of the American Heart Association, have detailed cardiometabolic considerations for...
Kommentare